ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.
about
Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacyRelationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.Surrogate markers for time-varying treatments and outcomesSome extensions in continuous models for immunological correlates of protection.Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition.A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine RegimensEvaluating a surrogate endpoint at three levels, with application to vaccine development.Statistical approaches for evaluating surrogate outcomes in clinical trials: A systematic review.Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.Links between causal effects and causal association for surrogacy evaluation in a gaussian setting.Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy.Design and estimation for evaluating principal surrogate markers in vaccine trials.A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpointEvaluation and comparison of predictive individual-level general surrogates.Surrogacy assessment using principal stratification and a Gaussian copula model.Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.
P2860
Q30714941-122838A6-BA66-4610-8D0A-4F1B191955D5Q33538308-79481D4F-0930-48DE-B0CF-755359D69728Q33621249-CA0CA1B5-A49C-4AEC-BEDB-A698601DF8F6Q34430200-B54E5F0B-3AA3-446F-AEE8-0FE3269EABD1Q35862314-BC5ECF7A-FF22-4C8F-B78A-D0A56FE8990BQ35862680-7CA02591-39DF-498B-8E0B-06C9CB262A63Q35878996-01B0457A-EF3C-4398-AB50-CDB8E441C6F3Q36407392-EAD2CA34-37FF-459C-BB2B-284DB4DBFBB7Q36413788-D7F41A8A-1E9A-4E19-BFE7-90A905F42DB8Q37107029-DFD417BC-9E36-468D-BAEE-ED90F2493EE8Q38590481-1963E091-77A3-45DD-BF34-5493472A55E7Q38796580-AD81027B-5099-4E32-A03A-EF79EDF2FD78Q38951699-2D6677D7-097E-492A-A411-1B7456DC43B4Q38982807-2F1CF375-0FCA-4E3A-AB5B-673C33BCAF5BQ39467318-E2BC0621-39A0-4598-AA50-8672D5C918EFQ41812285-0AA4F79A-26AE-45C5-8352-B72194C2A845Q41992194-CC522F70-EF5E-4D08-BD35-29F81EB6B808Q42057972-95035DDA-53B3-4933-A870-DC3DE47267EAQ46296261-10918498-6B96-4208-B725-1D468DA5B43D
P2860
ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ASSESSING SURROGATE ENDPOINTS ...... RT SAMPLING AND THE COX MODEL.
@en
ASSESSING SURROGATE ENDPOINTS ...... RT SAMPLING AND THE COX MODEL.
@nl
type
label
ASSESSING SURROGATE ENDPOINTS ...... RT SAMPLING AND THE COX MODEL.
@en
ASSESSING SURROGATE ENDPOINTS ...... RT SAMPLING AND THE COX MODEL.
@nl
prefLabel
ASSESSING SURROGATE ENDPOINTS ...... RT SAMPLING AND THE COX MODEL.
@en
ASSESSING SURROGATE ENDPOINTS ...... RT SAMPLING AND THE COX MODEL.
@nl
P2093
P2860
P356
P1476
ASSESSING SURROGATE ENDPOINTS ...... RT SAMPLING AND THE COX MODEL.
@en
P2093
Dean Follmann
Dongfeng Li
Peter B Gilbert
P2860
P304
P356
10.1214/07-AOAS132
P577
2008-03-01T00:00:00Z